Navigation Links
Ikaria(R) Names New Chairman
Date:10/19/2009

CLINTON, N.J., Oct. 19 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that Board Chairman David E. Shaw is retiring from the board. Current Ikaria CEO Daniel Tasse has been named Chairman of the Board, succeeding Shaw, who has served as Chairman since 2007.

Shaw was a founding investor and director in Ikaria, Inc., a biotechnology company that was formed in 2005, and was instrumental in combining it with INO Therapeutics in 2007 to form Ikaria Holdings, Inc. The transaction, valued at $670M, was led by New Mountain Capital and included ARCH Venture Partners and Venrock. Shaw served as founding CEO until Tasse's appointment as Director, President and CEO in January 2008. He is active in other private and public companies, and serves as Managing Partner of Black Point Group and a partner at Venrock.

"Ikaria exists and flourishes today because of the direction David Shaw established for the company from the beginning, including its focus on critical care and the formation of a strong and experienced management team," said Daniel Tasse, Chairman and CEO of Ikaria. "We thank David for his vision and leadership and wish him continued success in his future endeavors."

Prior to joining Ikaria in January 2008, Tasse served as General Manager of the $2 billion Pharmaceuticals & Technologies business of Baxter International, Inc., a division which was created by integrating the company's Anesthesia, Critical Care and BioPharma Solutions units. Prior to his tenure at Baxter International, Tasse held management positions at GlaxoSmithKline and Upjohn. He has a B.Sci. in Biochemistry from the University of Montreal.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOmax® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. The company also recently acquired the exclusive worldwide licenses to BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction, as well as to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute liver and kidney injury. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

SOURCE Ikaria Holdings, Inc.


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
3. IKARIA(R) to In-License BioLineRxs BL-1040
4. KGI Names Kerry Howell Vice President for Advancement
5. Vical Names Andrew de Guttadauro Vice President, Corporate Development
6. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
7. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
8. CryoLife Names Philip Theodore as Vice President, General Counsel
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. PPD Names Daniel Darazsdi as Chief Financial Officer
11. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The global biotechnology services outsourcing market ... 2025, according to a new report by Grand ... of the function of outsourcing certain clinical and ... services outsourced, clinical trial management and contract manufacturing ... was the first pharmaceutical company to outsource its ...
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports Medicine ... Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long Island ... anterior cervical discectomy and fusion on a 42 year old female who was ...
(Date:1/18/2017)... PRUSSIA, PA (PRWEB) , ... January 18, 2017 ... ... clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt ... in engaging panel discussions to examine vital clinical research issues such as trial ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):